Zürich23°Partly cloudy
Filtered by Topic
Latest pharmaceuticals news and updates from Switzerland. AI-curated articles covering pharmaceuticals topics.
← Show All NewsNovartis
Novartis has suspended several experimental CAR-T cell therapy trials after three patients died from a rare, potentially fatal immune complication. The decision raises fresh questions about the risks and oversight of next-generation treatments for autoimmune disease.
about 2 hours ago · 1 source
Novartis
Novartis has halted several experimental CAR-T cell-therapy trials after three patients died from immune-related complications. The article should explain what rap-cel is, why the trials were suspended, the known risks of CAR-T treatments and what the decision means for patients and the wider Swiss pharmaceutical sector.
SWI swissinfo.ch
pharmaceuticals
An industry-backed study warns that changes to US pharmaceutical policy could cost Switzerland almost CHF95 billion by 2040. The scenarios include production moving to the United States and a new US approach to drug pricing, with potential consequences for Swiss growth and patients.
SWI swissinfo.ch
Geneva
Three Geneva-based non-profit drug developers are joining forces as funding for global health innovation comes under pressure. Their work includes treatments for malaria in newborns, hepatitis C and drug-resistant infections that commercial pharmaceutical companies have often neglected.
SWI swissinfo.ch
Roche
Roche subsidiary Genentech has secured worldwide rights, outside South Korea, to develop and market Hanmi Pharmaceutical’s experimental obesity treatment HM17321. The agreement could be worth up to $2.3 billion, although the drug remains in early-stage clinical trials.
SWI swissinfo.ch
pharmaceuticals
A new Swiss debate is emerging over the pharmaceutical industry’s future as US pricing pressure threatens the development and availability of new medicines in Switzerland. Industry representatives warn that weaker framework conditions could reduce the sector’s economic contribution and tax revenues.
SWI swissinfo.ch
Bern
CSL Behring has completed a restructuring at its Bern site that eliminated just under 10% of jobs, although more than 100 new roles were created during the transformation. The company says the changes are intended to strengthen the site’s long-term competitiveness.
SWI swissinfo.ch
business
In a major development for the Swiss pharmaceutical sector, South Korean contract manufacturer Samsung Biologics has submitted a CHF1.5 billion cash offer to acquire Polypeptide, a key Swiss producer of active pharmaceutical ingredients.
SWI swissinfo.ch
business
Australian pharmaceutical firm CSL Behring has announced plans for significant job cuts at its Bern facility. The move, reportedly affecting around 180 employees, has triggered a mandatory consultation procedure due to the scale of the planned redundancies.
SWI swissinfo.ch
pharmaceuticals
Swiss pharmaceutical exports to Russia maintain pre-war levels at CHF1.8 billion, raising questions about medical trade during international conflicts.
SWI swissinfo.ch
healthcare
Major Swiss pharmaceutical companies commit billions in US investments to avoid potential tariffs, while smaller drug developers face uncertainty.
SWI swissinfo.ch
economy
Economists warn of recession risk as US threatens 100% tariffs on Swiss pharmaceutical exports
SWI swissinfo.ch
healthcare
Swiss pharma giant to offer 55% discount on psoriasis drug Cosentyx through new direct sales channel
SWI swissinfo.ch
economy
Switzerland faces unprecedented 39% US tariffs, prompting urgent trade diversification efforts and concerns in pharmaceutical sector
SWI swissinfo.ch · +1 more
healthcare
Swiss regulator greenlights Coartem Baby, marking significant advancement in treating malaria in infants weighing between two and five kilos
SWI swissinfo.ch
healthcare
Despite being a pharmaceutical hub, Switzerland's limited engagement in new antibiotic development poses worldwide health risks
SWI swissinfo.ch
business
Swiss pharmaceutical giant reports 15% revenue growth and raises forecast for ninth consecutive quarter, defying analyst expectations.
SWI swissinfo.ch
healthcare
Regulator faces backlash for ordering deletion of articles about Ozempic and Wegovy, sparking censorship debate
SWI swissinfo.ch
